MetaCap

Arcutis Biotherapeutics (ARQT) vs Viridian Therapeutics (VRDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Viridian Therapeutics (VRDN) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, losing 1.3% versus a loss of 10.6%. Over five years, VRDN leads with a +63.7% price change compared with +58.1% for ARQT. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.33 billion), about 1.0 times the size.

Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -483.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARQT-10.61%VRDN-1.25%
+19%-20%-60%
Nov 21, 20251 yearNov 20, 2026
ARQT+44.91%VRDN+54.04%
+102%+2%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARQT versus VRDN key metrics
MetricARQTVRDN
Share price$26.36$29.96
Market cap$3.33B$3.40B
1-day change-2.98%-4.71%
YTD return-9.23%-3.73%
1-year return-10.61%-1.25%
5-year return+58.13%+63.72%
P/E ratio (TTM)119.82—
Forward P/E24.09—
EPS (TTM)$0.22$-3.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$376.07M$70.85M
Revenue growth (YoY)+91.34%+23359.93%
Net income (latest FY)$-16.14M$-342.60M
Gross margin90.24%—
Operating margin-3.25%-512.91%
Net margin-4.29%-483.57%
52-week high$34.80$34.29
52-week low$19.30$13.18
Distance from 52-week high-24.25%-12.63%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.19%+42.72%
Average volume2.58M2.14M
Shares outstanding126.46M113.56M
Employees354252
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
  • Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +91.34%).

About Arcutis Biotherapeutics

ARQT stock →

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

ARQT vs VRDN FAQ

Which is bigger, Arcutis Biotherapeutics or Viridian Therapeutics?

Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.33B for Arcutis Biotherapeutics (ARQT).

Which stock has performed better over the past year, ARQT or VRDN?

VRDN returned -1.25% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.

Are Arcutis Biotherapeutics and Viridian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons